Navigation Links
Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits

nt was achieved by patient controlled analgesia (PCA), whereby the patient was allowed to self administer a dose of M6G or morphine as required to control their pain. The study was randomised and double blind so that neither patient nor carer was aware of which treatment was being administered. The main purpose of the study was to demonstrate statistically that:

- Treatment with either M6G or morphine, particularly during PCA, results in similar levels of pain management; and

- Effective analgesic treatment during PCA results in lower levels of nausea and vomiting in patients receiving M6G compared to those receiving morphine.

In addition, other important side effect, efficacy and safety features were determined throughout the study.

Summary of Phase III trial (M6G022) results

1. M6G matches morphine for analgesic effect

Importantly for a novel pain product, the trial results unequivocally show that M6G is as good as morphine in terms of analgesia achieved in patients up to 48 hours post-operatively. Successful achievement of this first primary endpoint supports data from previous clinical trials of M6G and is an essential component in the product profile of M6G.

2. M6G shows significant reduction in post-operative nausea and vomiting compared to morphine

The trial results confirm the excellent potential of M6G as an analgesic with a clinically significant improved side effect profile compared to morphine. The study results show that patients receiving M6G experienced a 28% reduction in the severity of post-operative nausea and vomiting (PONV) in the key 6 - 24 hours after treatment (statistically significant, p=0.018).

In addition, the incidence of dry retching/vomiting in the M6G arm compared to the morphine arm in the 24 hour period after treatment was reduced by 32% ( statistically significant, p= 0.044). The incidence and severity of post-operative nausea in the M6G arm was 27% less than that observ
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
5. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy
9. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
10. Positive Statistical Analysis from Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement of Primary Endpoint
11. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
Post Your Comments:
(Date:12/24/2014)... MASON, Ohio , Dec. 23, 2014 /PRNewswire/ ... industry-leading treatment decision support to healthcare providers for ... that it has secured $30 million in equity ... Virginia C. Drosos , President and Chief ... increased clinical adoption and development of Assurex Health,s ...
(Date:12/24/2014)... Va. , Dec. 23, 2014  The ... diastolic blood pressure target for people with diabetes ... moderate or high doses of statins, in keeping ... management enacted by the American College of Cardiology ... are reflected in the most recent changes to ...
(Date:12/24/2014)... , Dec. 23, 2014 In response to urgent ... of Sierra Leone , Direct Relief delivered ... for the treatment of local health workers who contract ... new dedicated Ebola care center was constructed for foreign health ... is not available for local Sierra Leonean health workers. ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced ... Citi 2011 Global Health Care Conference on Thursday, ... Hilton New York Hotel in New York City. Cowen ... 7, 2011 at 4:45 p.m. Eastern Time at The Boston ...
... March 1, 2011 / PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) ... biotechnology and medical device R&D outsourcing company with operations ... it will release financial results for the fourth quarter ... on Tuesday, March 8, 2011 (which will be Wednesday ...
Cached Medicine Technology:Optimer Pharmaceuticals to Present at March 2011 Investor Conferences 2WuXi PharmaTech Schedules Fourth-Quarter 2010 Earnings Release 2
(Date:12/25/2014)... (PRWEB) December 26, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. TS-1 is an anti-cancer drug which is typically ... and is also used for treating gastric cancer and ... otastat potassium. The drug was first approved in 1999 ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... December 25, 2014 Recently, LunaDress.co.uk has updated its ... and related accessories. Now, all of the models at LunaDress.co.uk come ... a groom lifts the wedding veil can turn out to be ... charm. A wedding veil can always bring surprise to a wedding. ... on how to choose veils for a big day . ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... of youth" drug that can delay the effects of aging ... suggests. Seniors received a significant boost to their immune ... pathway linked to aging and immune function, researchers with the ... a version of the drug rapamycin, improved the seniors, immune ...
(Date:12/25/2014)... 2014 Residents at Abernethy ... showed their generous spirit by providing holiday gifts ... Parenting Network- Grandparents Raising Grandchildren program. , Following ... the largest Christmas tree on the campus of ... residents of the Abernethy Village Association (AVA). Each ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2
... Health Organization (WHO) figures show that each year an ... in the world. The growth of this disease remains ... of HIV patients (nearly 13% compared with less than ... the world is experiencing accelerating advance of a deadly ...
... Dog On It! Fortified Juice Beverages for Kids Pledges up to ... $650,000 for Type 1 Diabetes Research, ... Dog On,It! fortified juice beverage for kids, announced today the launch ... the world,s leading charitable funder of type 1,diabetes research., As ...
... RICHMOND, Calif., March 5 Transcept,Pharmaceuticals, Inc. today ... Chief Financial Officer, will present at Cowen and ... Marriott Copley Place on,Thursday, March 20, 2008 at ... Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical ...
... On Saturday, March,29 at 8:00 am, the Bowen ... Waters Park in Annapolis to raise money to fight ... experience a beautiful 5K,waterfront course complete with activities for ... proceeds from the event go toward the Bowen,Foundation, an ...
... for oil exploration now researchers at The University ... steroid test using hydropyrolysis. , The process which ... and make-up of a sample has been refined ... tests for detecting levels of illicit steroids in urine. ...
... Corporation,(ADAMS), the leading provider of program management and ... of Deborah (Debbie) J.,Aiken and Brandon L. Cannaday ... have joined ADAMS as Associate Project Managers within ... both based out of ADAMS,Cleveland, Ohio office location ...
Cached Medicine News:Health News:A new more effective tuberculosis screening test for HIV victims 2Health News:A new more effective tuberculosis screening test for HIV victims 3Health News:White Hat Brands, Juvenile Diabetes Research Foundation Offer the 'Juice' on New Partnership 2Health News:White Hat Brands, Juvenile Diabetes Research Foundation Offer the 'Juice' on New Partnership 3Health News:Inaugural Bowen Foundation Run/Walk to Fight Autism in Maryland Set for Saturday, March 29 2Health News:New steroid test uses oil exploration technique 2Health News:ADAMS Welcomes Debbie Aiken and Brandon Cannaday to the Firm's Staff as Associate Project Managers 2Health News:ADAMS Welcomes Debbie Aiken and Brandon Cannaday to the Firm's Staff as Associate Project Managers 3
... Cardiology specific EMR / PM system ... nationwide,enabling more effective patient care decisions.,AcerMed's ... clinicians with critical information on a ... care.,Our Cardiology specific clinical pathways have ...
...
... is estimated that 25% of women and 15% ... United States, more than half of adults over ... unsightly venous disease., The VenaCure Laser Vein Treatment ... the treatment of varicose veins. VenaCure offers your ...
ELVeS is a new minimally-invasive laser treatment for patients with superficial vein reflux of the greater saphenous vein. The ELVeS laser treatment offers your patients an effective out-patient alt...
Medicine Products: